DE60033180D1 - Auf dem rinderimmunschwächevirus (biv) basierte vektoren - Google Patents

Auf dem rinderimmunschwächevirus (biv) basierte vektoren

Info

Publication number
DE60033180D1
DE60033180D1 DE60033180T DE60033180T DE60033180D1 DE 60033180 D1 DE60033180 D1 DE 60033180D1 DE 60033180 T DE60033180 T DE 60033180T DE 60033180 T DE60033180 T DE 60033180T DE 60033180 D1 DE60033180 D1 DE 60033180D1
Authority
DE
Germany
Prior art keywords
biv
gene
vectors
operably linked
packaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60033180T
Other languages
English (en)
Other versions
DE60033180T2 (de
Inventor
Tianci Luo
David Berkowitz
Michael Kaleko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/734,836 external-priority patent/US6864085B2/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE60033180D1 publication Critical patent/DE60033180D1/de
Application granted granted Critical
Publication of DE60033180T2 publication Critical patent/DE60033180T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60033180T 1999-12-14 2000-12-13 Auf dem rinderimmunschwächevirus (biv) basierte vektoren Expired - Lifetime DE60033180T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US734836 1991-07-24
US46446099A 1999-12-14 1999-12-14
US464460 1999-12-14
US24949200P 2000-11-17 2000-11-17
US249492P 2000-11-17
US09/734,836 US6864085B2 (en) 1999-12-14 2000-12-12 Bovine immunodeficiency virus (BIV) based vectors
PCT/US2000/033725 WO2001044458A2 (en) 1999-12-14 2000-12-13 Bovine immunodeficiency virus (biv) based vectors

Publications (2)

Publication Number Publication Date
DE60033180D1 true DE60033180D1 (de) 2007-03-15
DE60033180T2 DE60033180T2 (de) 2007-10-25

Family

ID=27400217

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60033180T Expired - Lifetime DE60033180T2 (de) 1999-12-14 2000-12-13 Auf dem rinderimmunschwächevirus (biv) basierte vektoren
DE60043870T Expired - Lifetime DE60043870D1 (de) 1999-12-14 2000-12-13 Auf bovinem Immundefizienvirus (BIV) basierende Vektoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60043870T Expired - Lifetime DE60043870D1 (de) 1999-12-14 2000-12-13 Auf bovinem Immundefizienvirus (BIV) basierende Vektoren

Country Status (10)

Country Link
EP (2) EP1852511B1 (de)
JP (3) JP2003517312A (de)
AT (2) ATE352636T1 (de)
AU (1) AU778110B2 (de)
CA (1) CA2392221C (de)
DE (2) DE60033180T2 (de)
ES (2) ES2340073T3 (de)
IL (2) IL149704A0 (de)
NZ (1) NZ519034A (de)
WO (1) WO2001044458A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2170622B1 (es) 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
IL149704A0 (en) * 1999-12-14 2002-11-10 Novartis Ag Bovine immunodeficiency virus (biv) based vectors
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
IL157335A0 (en) 2001-03-13 2004-02-19 Novartis Ag Lentiviral packaging constructs
AU2002327412A1 (en) 2001-08-02 2003-02-17 Institut Clayton De La Recherche Methods and compositions relating to improved lentiviral vector production systems
NZ532060A (en) 2001-10-02 2005-11-25 Inst Clayton De La Rech Methods and compositions relating to restricted expression lentiviral vectors and their applications
ES2208051B1 (es) * 2002-01-24 2005-08-16 Consejo Sup. Investig. Cientificas Secuencia de acido nucleico que comprende la señal de encapsidacion del rna de un coronavirus del grupo 1 y sus aplicaciones.
CN1643164A (zh) * 2002-02-04 2005-07-20 诺瓦提斯公司 以重组牛免疫缺陷病毒为基础的基因转移系统
GB2450688A (en) * 2005-05-11 2009-01-07 Viragen Inc Ovalbumin promoter constructs for retroviral vectors
US10072067B2 (en) * 2014-01-30 2018-09-11 Children's Hospital Medical Center Fetal hemoglobin for genetic correction of sickle cell disease
GB202114532D0 (en) * 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral Vectors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380830A (en) * 1989-09-18 1995-01-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Molecular clones of bovine immunodeficiency-like virus
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
FR2768743B1 (fr) 1997-09-23 2001-09-14 Bio Merieux Procede de lyse de micro-organisme
ES2245042T3 (es) * 1997-09-24 2005-12-16 The Regents Of The University Of California Vectores de lentivirus de no primates y sistemas de empaquetamiento.
AU763007B2 (en) * 1998-05-22 2003-07-10 Oxford Biomedica (Uk) Limited Retroviral delivery system
IL149704A0 (en) * 1999-12-14 2002-11-10 Novartis Ag Bovine immunodeficiency virus (biv) based vectors

Also Published As

Publication number Publication date
AU2259801A (en) 2001-06-25
JP2014110789A (ja) 2014-06-19
IL149704A (en) 2013-02-28
EP1238092B1 (de) 2007-01-24
AU778110B2 (en) 2004-11-18
WO2001044458A2 (en) 2001-06-21
EP1852511A1 (de) 2007-11-07
JP2010166919A (ja) 2010-08-05
ES2281369T3 (es) 2007-10-01
DE60043870D1 (de) 2010-04-01
CA2392221A1 (en) 2001-06-21
ES2340073T3 (es) 2010-05-28
DE60033180T2 (de) 2007-10-25
ATE458062T1 (de) 2010-03-15
WO2001044458A3 (en) 2001-11-29
ATE352636T1 (de) 2007-02-15
CA2392221C (en) 2012-01-31
IL149704A0 (en) 2002-11-10
EP1852511B1 (de) 2010-02-17
JP2003517312A (ja) 2003-05-27
EP1238092A2 (de) 2002-09-11
NZ519034A (en) 2005-02-25

Similar Documents

Publication Publication Date Title
RU2733832C1 (ru) Искусственный ген Stbl_RBD_TrM_SC2, кодирующий бицистронную структуру, образованную последовательностями рецепторсвязывающего домена гликопротеина S коронавируса SARS-CoV-2, трансмембранного региона, P2A-пептида и гликопротеина G VSV, рекомбинантная плазмида pStem-rVSV-Stbl_RBD_TrM_SC2, обеспечивающая экспрессию искусственного гена, и рекомбинантный штамм вируса везикулярного стоматита rVSV-Stbl_RBD_TrM_SC2, используемый для создания вакцины против коронавируса SARS-CoV-2
Hahn et al. Infectious Sindbis virus transient expression vectors for studying antigen processing and presentation.
Binley et al. Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins
Jeffers et al. Covalent modifications of the ebola virus glycoprotein
Chambers et al. Nucleotide sequence of the gene encoding the fusion glycoprotein of Newcastle disease virus
Pinter et al. Localization of the labile disulfide bond between SU and TM of the murine leukemia virus envelope protein complex to a highly conserved CWLC motif in SU that resembles the active-site sequence of thiol-disulfide exchange enzymes
Donson et al. The nucleotide sequence of a geminivirus from Digitaria sanguinalis
DE60033180D1 (de) Auf dem rinderimmunschwächevirus (biv) basierte vektoren
ATE291632T1 (de) Auf lentivirus basierende gentransfer-vektoren
DK28191A (da) Dna-planteekspressionskassette og dennes anvendelse
DK1224314T3 (da) Lentiviralt triplex-DNA samt vektorer og rekombinante celler indeholder lentiviralt triplex-DNA
DK0490972T3 (da) Ekspressionssystemer for rekombinante negativstreng-RNA-vira og vacciner
Dash et al. Deletion of a single N-linked glycosylation site from the transmembrane envelope protein of human immunodeficiency virus type 1 stops cleavage and transport of gp160 preventing env-mediated fusion
Du et al. Efficient replication and generation of recombinant bovine adenovirus‐3 in nonbovine cotton rat lung cells expressing I‐SceI endonuclease
RU2733831C1 (ru) Искусственный ген, кодирующий бицистронную структуру, образованную последовательностями рецептор-связующего домена гликопротеина S коронавируса SARS-CoV-2, P2A-пептида и гликопротеина G VSV, рекомбинантная плазмида pStem-rVSV-Stbl_RBD_SC2, обеспечивающая экспрессию искусственного гена и рекомбинантный штамм вируса везикулярного стоматита rVSV-Stbl_RBD_SC2, используемого для создания вакцины против коронавируса SARS-CoV-2
PT632129E (pt) Vectores recombinantes de virus sincicial para utilizacoes medicinais e de diagnostico e processos para a preparacao de vectores recombinantes de virus sincicial
ATE258987T1 (de) Helfersystem zur wirkungssteigerung der aav- vektorproduktion
Beyer et al. Recombinant expression of lymphocytic choriomeningitis virus strain WE glycoproteins: a single amino acid makes the difference
Gaudin et al. Soluble ectodomain of rabies virus glycoprotein expressed in eukaryotic cells folds in a monomeric conformation that is antigenically distinct from the native state of the complete, membrane-anchored glycoprotein
JP2004524805A5 (de)
Davies et al. Structure and replication of geminivirus genomes
Nakayama et al. Leucine at position 278 of the AIK-C measles virus vaccine strain fusion protein is responsible for reduced syncytium formation
Alkhatib et al. Characterization of a cleavage mutant of the measles virus fusion protein defective in syncytium formation
Morimoto et al. Comparison of rabies virus G proteins produced by cDNA-transfected animal cells that display either inducible or constitutive expression of the gene
WO2002008436A3 (en) Mini-adenoviral vector system for vaccination

Legal Events

Date Code Title Description
8364 No opposition during term of opposition